Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
about
Abronione, a rotenoid from the desert annual Abronia villosaSynergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine ModelTargeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathwayIdentification of the plant compound geraniin as a novel Hsp90 inhibitorDeguelin suppresses pancreatic tumor growth and metastasis by inhibiting epithelial-to-mesenchymal transition in an orthotopic model.Deguelin inhibits non-small cell lung cancer via down-regulating Hexokinases II-mediated glycolysis.Gambogic acid, a natural product inhibitor of Hsp90Carbon monoxide promotes VEGF expression by increasing HIF-1alpha protein level via two distinct mechanisms, translational activation and stabilization of HIF-1alpha protein.Deguelin induces both apoptosis and autophagy in cultured head and neck squamous cell carcinoma cells.Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway.Deguelin induces apoptosis by targeting both EGFR-Akt and IGF1R-Akt pathways in head and neck squamous cell cancer cell lines.The combination of tephrosin with 2-deoxy-D-glucose enhances the cytotoxicity via accelerating ATP depletion and blunting autophagy in human cancer cells.Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.Deguelin inhibits retinal neovascularization by down-regulation of HIF-1alpha in oxygen-induced retinopathyA multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.Deguelin inhibits vasculogenic function of endothelial progenitor cells in tumor progression and metastasis via suppression of focal adhesion.Regulation of ROS production and vascular function by carbon monoxideFermented barley and soybean (BS) mixture enhances intestinal barrier function in dextran sulfate sodium (DSS)-induced colitis mouse modelInsulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.Humanized anti-hepatocyte growth factor (HGF) antibody suppresses innate irinotecan (CPT-11) resistance induced by fibroblast-derived HGF.Novel C6-substituted 1,3,4-oxadiazinones as potential anti-cancer agents.Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradationA novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1alpha.Kava, a tonic for relieving the irrational development of natural preventive agents.Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells.A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy.Liposomal encapsulation of deguelin: evidence for enhanced antitumor activity in tobacco carcinogen-induced and oncogenic K-ras-induced lung tumorigenesis.Decursin inhibits retinal neovascularization via suppression of VEGFR-2 activation.Hemin, an iron-binding porphyrin, inhibits HIF-1α induction through its binding with heat shock protein 90.Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibitionDeguelin and Its Role in Chronic Diseases.Hypoxia-mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1α destabilization by SH-1242 and SH-1280, novel hsp90 inhibitors.Heat shock proteins and kidney disease: perspectives of HSP therapy.Delivering instilled hydrophobic drug to the bladder by a cationic nanoparticle and thermo-sensitive hydrogel composite system.Deguelin-induced blockade of PI3K/protein kinase B/MAP kinase signaling in zebrafish and breast cancer cell lines is mediated by down-regulation of fibroblast growth factor receptor 4 activity.High-content screening of drug-induced cardiotoxicity using quantitative single cell imaging cytometry on microfluidic device.Simultaneous quantitative monitoring of drug-induced caspase cascade pathways in carcinoma cells.
P2860
Q24632579-AD51D898-DFAF-4513-B389-FFA3F73E203CQ27312452-E33A8957-64CF-466C-8636-0DC39D0CED2AQ28382812-B8262DCD-1E51-4D02-A44A-1C1D2F755D09Q28533486-19FBBCAB-0E08-4125-8218-B8F208F0358BQ30530734-A769932D-743E-4591-81DA-CC23430C2D3EQ33779169-435B3187-8FA5-41A5-9E43-6AD666F064C9Q33870322-21807221-E07A-4AAB-9713-01E25DB7472BQ34186417-58D7BED9-3D24-4E91-98C8-684F55EEC2C0Q34571304-80D1628E-CBD1-4CF2-9FCD-41DC2236C8CDQ35147446-2F0A72B4-E50F-4390-B149-30B5EF516F41Q35667885-9DCD3DE4-056A-485C-9B58-276A177FEE81Q35760966-CA70D860-1A75-4C6A-84B5-5FD5EE58DE14Q35800838-6198E226-1AA4-4493-A4A3-84F209BCE4FFQ35886681-B0DB94F1-B2C0-45DE-A081-3E6052036B1AQ36031062-F9596522-933D-48C9-9243-22ED675F89BDQ36140879-28A7EA05-5691-4CD9-84F8-9DB7357F0575Q36183868-D9A3A008-D6CD-4D33-8D2A-F8E44EEBB19CQ36212298-2322999F-13CD-4170-ABD2-14B8E67281DDQ36300954-61CDE238-32BE-447A-9DB9-EAE2C81E4B02Q36414376-986F90D9-544C-40C3-B93C-4ACCF26EA641Q36562098-F04B2813-9E4C-4657-9520-E7C74580172BQ36767863-0515EC1C-0862-4D6C-92B2-80C867406084Q36800387-0FAAD3B2-E851-4045-906C-54CB935CE7D1Q37077443-3DA5012C-3904-4E46-BD6A-561F575101E1Q37106192-E874347C-27E9-4B5F-979C-A36F04FCF3E4Q37175348-01C1869F-1331-4C92-A694-ABBF599C6D0DQ37228635-84142011-88BE-43FD-8A86-CF9441DFCFD0Q37334829-87D570B0-34CE-4D95-ACA5-40C6966DD02EQ37345190-34502295-DDC2-4809-A23C-B8F8FFEA7BB1Q37346456-8436CC03-264F-4FD7-BDB0-6A4A6A7E2F0CQ38476087-D2262B55-88CB-49A8-81AC-18910872412EQ38750417-48D76146-55AE-44AF-AE4F-5A9F92BCCD00Q38823644-5E7D9329-114E-48C7-8811-44B8DCFEB933Q38988602-7DA55515-F7B4-48C1-9993-74898577B13FQ38990297-170155ED-E137-4984-8018-847ABC7639FEQ39242393-D84BF1A6-5253-42FA-8993-604FB48FFF95Q39284112-7ED935D6-95C6-47E3-BD15-CADE0B7C72EDQ39382063-080431C9-BC93-4928-A2CE-13B7CB9A09C0Q39634258-3401A1F5-D719-460E-AE67-AC1111CF7791Q39703393-4939C310-2415-40F4-9591-831E7A2E6A04
P2860
Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
@ast
Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
@en
Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
@nl
type
label
Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
@ast
Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
@en
Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
@nl
prefLabel
Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
@ast
Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
@en
Structural basis for depletion of heat shock protein 90 client proteins by deguelin.
@nl
P2093
P2860
P356
P1476
Structural basis for depletion of heat shock protein 90 client proteins by deguelin
@en
P2093
Ho-Young Lee
Hyun-Ju Park
Jeffrey N Myers
Kyu-Won Kim
Quanri Jin
Seung Hyun Oh
Soon Sun Hong
Waun Ki Hong
Woo-Young Kim
Yasemin Dakak Yazici
P2860
P304
P356
10.1093/JNCI/DJM007
P407
P50
P577
2007-06-12T00:00:00Z